Novel inhibitors in the treatment of metastatic melanoma

References

• American Cancer Society. Cancer Facts and Figures 2006. American Cancer Society Inc. Atlanta, GA, USA 1–21 (2007).
   Google Scholar
• Balch C, Buzaid A, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol.19, 3635–3648 (2001).
   PubMed Web of Science ®Google Scholar
• Gogas H, Kirkwood J, Sondak V, Helen J, Gogas MD. Chemotherapy for metastatic melanoma: time for a change? Cancer109(3), 455–464 (2007).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17, 2105–2116 (1999).
   PubMed Web of Science ®Google Scholar
• Phan G, Attia P, Steinberg S et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol.19(15), 3477–3482 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenberg S, Yang J, White D et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg.228(3), 307–319 (1998).
   PubMed Web of Science ®Google Scholar
• Goel V, Lazar A, Warneke C, Redston M, Haluska F. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol.126, 154–160 (2006).
   PubMed Web of Science ®Google Scholar
• Davies H, Bigness GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417, 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Pollock PM, Harper UL, Hansen KS et al. High frequency of BRAF mutations in nevi. Nat. Genet.33, 19–20 (2003).
   PubMed Web of Science ®Google Scholar
• Daniotti M, Oggionni M, Ranzani T et al. BRAF alterations are associated with complex mutational profiles in malignancy melanoma. Oncogene23, 5968–5977 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar R, Angelini S, Czene K et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res.9, 3362–3368 (2003).
   PubMed Web of Science ®Google Scholar
• Houben R, Becker JC, Kappel A et al. Constitutive activation of the Ras–Raf signaling pathway in metastatic melanoma is associated with poor prognosis (abstract). J. Carcinogenesis3, 6 (2004).
   Google Scholar
• Rodriguez-Viciana P, Marte BM, Warne PH, Downward J. Phosphatidylinositol 3´kinase: one of the effectors of Ras. Philos. Trans. R. Soc. London B Biol. Sci.351, 225–231; discussion 231–222 (1996).
   PubMedGoogle Scholar
• Wu Heng, Goel V, Haluska F. PTEN signaling pathways in melanoma. Oncogene22, 3113–3122 (2003).
   PubMed Web of Science ®Google Scholar
• Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene16, 3397–3402 (1998).
   PubMed Web of Science ®Google Scholar
• Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res.57, 3660–3663 (1997).
   PubMed Web of Science ®Google Scholar
• Goel V, Lazar A, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol.126, 154–160 (2006).
   PubMed Web of Science ®Google Scholar
• Tsao H, Mihm MC, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi and cutaneous melanoma. J. Am. Acad. Dermatol.49, 865–872 (2003).
   PubMed Web of Science ®Google Scholar
• Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression. Cancer Res.62, 7335–7342 (2002).
   PubMed Web of Science ®Google Scholar
• Dai D, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol.23(7), 1473–1482 (2005).
   PubMed Web of Science ®Google Scholar
• Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J. Clin. Invest.115(4), 813–824 (2005).
   PubMed Web of Science ®Google Scholar
• Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol.122(2), 337–341 (2004).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Karasarides M, Chiloeches A, Hayward R et al. B-RAF is a therapeutic target in melanoma. Oncogene23, 6292–6298 (2004).
   PubMed Web of Science ®Google Scholar
• Strumberg D, Voliotis D, Moeller JG et al. Results of Phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int. J. Clin. Pharmacol. Ther.40, 580–581 (2002).
   PubMedGoogle Scholar
• Richly H, Kupsch P, Passage K et al. A Phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int. J. Clin. Pharmacol. Ther.41, 620–621 (2003).
   PubMedGoogle Scholar
• Escudier B, EisenT, Staler WM. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT. Sorafenib in advanced melanoma: a Phase II randomized discontinuation trial analysis. Br. J. Cancer95(5), 581–586 (2006).
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lee RJ, Humphries R. Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P). Proc. Am. Soc. Clin. Oncol.22, 410 (2003).
   Google Scholar
• Lorigan P, Corie P, Chao D et al. Phase II trial investigating safety and preliminary efficacy of sorafenib combined with dacarbazine in metastatic melanoma patients. Presented at: American Society of Clinical Oncology Poster Discussion. June 2–6, Atlanta, GA, USA (2006).
   PubMedGoogle Scholar
• Flaherty KT, Lee RJ, Humphries R. Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paclitaxel (P). Proc. Am. Soc. Clin. Oncol.22, 410 (2003).
   Google Scholar
• Solit D, Garraway LA, Pratilas CA. BRAF mutation predicts sensitivity to MEK inhibition. Nature439(7074), 358–362 (2006).
   PubMed Web of Science ®Google Scholar
• Margolin K, Longmate J, Baratta T et al. CCI-779 in metastatic melanoma: a Phase II trial of the California Cancer Consortium. Cancer104(5), 1045–1048 (2005).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. A Phase 3, randomized, three-arm study of temsirolimus or interferon-α or the combination of temsirolimus + interferon in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. J. Clin. Oncol.24(18 Suppl.), LBA4 (2006).
   Google Scholar
• Wan X, Harkavy B, Shen N et al. Rapamycin induces feedback activation of AKT signaling through an IGF-1R-dependent mechanism. Onocogene26(13), 1932–1940 (2007).
   PubMed Web of Science ®Google Scholar
• King R, Deashaies R, Peters J et al. How proteolysis drives the cell cycle. Science274, 1652–1659 (1996).
   PubMed Web of Science ®Google Scholar
• Hamilton A, Eder J, Pavlick J et al. Proteasome inhibition with bortezomib (PS-341): a Phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J. Clin. Oncol.23(25), 6107–6116 (2005).
   PubMed Web of Science ®Google Scholar
• Richardson P, Barlogie B, Berenson J et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med.348, 2609–2617 (2003).
   PubMed Web of Science ®Google Scholar
• Markovic S, Geyer S, Dawkins F et al. A Phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer103(12), 2584–2589 (2005).
   PubMed Web of Science ®Google Scholar
• Soengas M, Lowe S. Apoptosis and melanoma chemoresistance. Oncogene22, 3138–3152 (2003).
   PubMed Web of Science ®Google Scholar
• Bedikian A, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol.24(29), 4738–4745 (2006).
   PubMed Web of Science ®Google Scholar
• Leiter U, Schmid R, Kaskel P et al. Antiapoptotic Bcl-2 and Bcl-xl in advanced malignant melanoma. Arch. Dermatol. Res.292(5), 225–232 (2000).
   PubMed Web of Science ®Google Scholar
• Zhuang L, Lee C, Scolyer R et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol.20(4), 416–426 (2007).
   PubMed Web of Science ®Google Scholar
• Krause D, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med.353, 172–187 (2005).
   PubMed Web of Science ®Google Scholar
• Carroll M, Ohno-Jones S, Tamura S et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR–ABL, TEL–ABL, and TEL–PDGFR fusion proteins. Blood90, 4947–4952 (1997).
   PubMed Web of Science ®Google Scholar
• Curtin J, Busam K, Pinkel D, Bastian B. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol.24(26), 4340–4346 (2006).
   PubMed Web of Science ®Google Scholar
• Heldin CH, Wetermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev.79, 1283–1316 (1999).
   PubMed Web of Science ®Google Scholar
• Shen SS, Zhange PF, Eton O, Prieto VG. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J. Cutaneous Pathol.30, 539–547 (2003).
   PubMed Web of Science ®Google Scholar
• Redondo P, Lloret P, Andreu EJ et al. Imatinib mesylate in cutaneous melanoma. J. Invest. Dermatol.123(6), 1208–1209 (2004).
   PubMedGoogle Scholar
• McGary EC, Onn A, Mills L et al. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J. Invest. Dermatol.122(2), 400–405 (2004).
   PubMedGoogle Scholar
• Grossman D. Imatinib mesylate for melanoma: will a new target be revealed? J. Invest. Dermatol.123(6), XI–XIII (2004).
   PubMedGoogle Scholar
• Curtin J, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med.353, 2135–2147 (2005).
   PubMed Web of Science ®Google Scholar
• Wyman K, Atkins MB, Prieto V et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer106(9), 2005–2011 (2006).
   PubMed Web of Science ®Google Scholar
• Eton O, Billings L, Kim K et al. Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma. J. Clin. Oncol.22(14S), 7528 (2004).
   Google Scholar